Investigators have found that dasatinib, a drug commonly used to treat chronic myeloid leukemia, is strongly associated with kidney injury. The study team strongly believes this study will impact clinical practice significantly, changing standard of care and possibly introducing new black box warnings for dasatinib. Furthermore, the researchers point out that the incidence of kidney injury is a previously unknown severe side effect for this drug. This side effect, they report, is advertised to be rare; however, they observed it in 10% of all participants taking dasatinib. Of concern, they say, is that patients taking dasatinib are currently not screened...